Last year, South Africa launched a new HIV treatment, called dolutegravir.
Back then, research indicated that the pill could be linked to an increased risk of defects in babies’ brains if women fell pregnant while using it. Or, if they were taking dolutegravir during the early stages of pregnancy.
Now, new research has found that, in fact, birth defects are no more likely when pregnant women are taking dolutegravir than with other antiretrovirals.
*This video was produced by the Bhekisisa Centre for Health Journalism. Sign up for the newsletter.
Image credit: Baz Ratner